Drug Launch Timing and International Reference Pricing
Article first published online: 7 JUL 2014
Copyright © 2014 John Wiley & Sons, Ltd.
Volume 24, Issue 8, pages 978–989, August 2015
How to Cite
2015), Drug Launch Timing and International Reference Pricing. Health Econ., 24, 978–989. doi: 10.1002/hec.3078., and (
- Issue published online: 2 JUL 2015
- Article first published online: 7 JUL 2014
- Manuscript Accepted: 27 MAY 2014
- Manuscript Revised: 5 MAR 2014
- Manuscript Received: 20 FEB 2013
- drug launch timing;
- international reference pricing
This paper analyzes the timing decisions of pharmaceutical firms to launch a new drug in countries involved in international reference pricing. We show three important features of launch timing when all countries refer to the prices in all other countries and in all previous periods of time. First, there is no withdrawal of drugs in any country and in any period. Second, whenever the drug is sold in a country, it is also sold in all countries with larger willingness to pay. Third, there is no strict incentive to delay the launch of a drug in any country. We then show that the first and third results continue to hold when the countries only refer to the prices of a subset of all countries in a transitive way and in any period. We also show that the second result continues to hold when the reference is on the last period prices only. Last, we show that the seller's profits increase as the sets of reference countries decrease with respect to inclusion. Copyright © 2014 John Wiley & Sons, Ltd.